Modigene to Present at the BIO-Europe Spring(R) 2009 Conference

NES-ZIONA, Israel, March 10 /PRNewswire/ — Modigene Inc. (OTC Bulletin Board: MODG), a biopharmaceutical company developing a long-acting human growth hormone and other proprietary longer-acting versions of already approved therapeutic proteins, today announced that CEO Avri Havron will present at the upcoming BIO-Europe Spring(R) 2009 Conference at 10:00 AM (local time) on March 17, 2009. The conference will be held at the Milano Convention Center in Milan, Italy from March 16-18, 2009.

For more information about the BIO-Europe Spring(R) 2009 Conference, visit http://www.ebdgroup.com/bes/

ABOUT MODIGENE

Modigene Inc. is a biopharmaceutical company applying its patented CTP technology to develop longer-acting, proprietary versions of already approved therapeutic proteins that currently generate billions of dollars in annual global sales. The CTP technology is applicable to virtually all proteins, and Modigene is currently developing long-acting versions of human growth hormone, interferon beta and erythropoietin, which are in late preclinical development, as well as GLP-1. For more information on Modigene, visit www.modigeneinc.com.

    MODIGENE CONTACT:                         MEDIA CONTACT:
    Shai Novik, President                     Barbara Lindheim
    Modigene Inc.                             GendeLLindheim BioCom Partners
    Tel: +1 866 644-7811                      +1 212 918-4650
    Email: shai@modigeneinc.com

SOURCE Modigene Inc.